CTOs on the Move

Savara Pharmaceuticals

www.savarapharma.com

 
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.savarapharma.com
  • 6836 Bee Cave Road Building 3, Suite 200
    Austin, TX USA 78746
  • Phone: 512.961.1891

Executives

Name Title Contact Details

Funding

Savara Pharmaceuticals raised $18.54M on 12/17/2015
Savara Pharmaceuticals raised $47M on 10/26/2017
Savara Pharmaceuticals raised $26.8M on 01/15/2020
Savara Pharmaceuticals raised $130M on 03/11/2021

Similar Companies

In Harmony Inc

In Harmony Inc is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Momentum for Health

CARF-accredited: Largest private nonprofit agency in Santa Clara County providing mental health services to over 3800 youth, adults and older adults annually.

Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.

hope pharma inc

hope pharma inc is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.